TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03782090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial intubation
Description: 1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial intubation
Description: 1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated.
Study: NCT03226964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal oxygen
Description: humidified high flow nasal oxygen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen
Description: humidified high flow nasal oxygen
Study: NCT01974037

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NaCl
Description: NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NaCl
Description: NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NaCl
Description: NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
Study: NCT02666287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
Study: NCT00998075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole - Nexium
Description: Clinical Trial Capsule or MUPS Tablet, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Tablet, oral, single dose
Study: NCT01864070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
Study: NCT03100968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Traditional epidural methods used for the identification of the midline using palpation prior to procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
Study: NCT02984761

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Pulmonary Resection
Description: An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
Study: NCT02034981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~* 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~* 165 mg/m² twice daily for ALCL patients aged from 1 to 17.
Study: NCT02666287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
Study: NCT01116648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo optional tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT01116648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04573257

Intervention type: OTHER
Intervention: Echocardiography and pulse wave velocity measurement
Description: Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement

Intervention type: OTHER
Intervention: Echocardiography and pulse wave velocity measurement
Description: Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement

Intervention type: OTHER
Intervention: Echocardiography and pulse wave velocity measurement
Description: Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
Study: NCT02666287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
Study: NCT00295763

Intervention type: DRUG
Group type: OTHER
Intervention: Thyrogen (thyrotropin alfa for injection)
Description: No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO.
Study: NCT03761537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT02850432

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive treatment
Description: Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: rehabilitation with medical therapy
Study: NCT03761498

Intervention type: OTHER
Intervention: Caloric Requirement
Description: Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
Study: NCT02317939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instruction
Description: online instruction tutorials at followup visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard baseline instruction
Description: self-guidance at followup visits
Study: NCT01116648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO
Study: NCT02137850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
Study: NCT04004065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesleteplirsen
Description: Vesleteplirsen injection, for IV use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesleteplirsen
Description: Vesleteplirsen injection, for IV use
Study: NCT03407157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Description: Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
Study: NCT00328614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
Study: NCT00761280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabedersen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug delivery system for administration of AP 12009
Description: Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Drug Delivery System
Description: Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Study: NCT03565042

Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopy of swollen joint (ankle/knee)
Study: NCT01489254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GTR)
Description: Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate (Copaxone®)
Description: Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Study: NCT04623034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine
Study: NCT03263832

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibiofilmogramme
Description: An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibiofilmogramme
Description: An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
Study: NCT04623034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine
Study: NCT03072238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
Study: NCT01959347

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Miduretheral Sling
Description: MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miduretheral Sling with behavioral/pelvic floor therapy
Description: MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
Study: NCT01146301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting